Abstract / Summary
Statins are marketed as antihyperlipidemic drugs, have been repurposed in cancer management. Their repurposing is based on antiproliferative, apoptotic, and anti-metastatic properties. Head and neck cancer, including oral carcinoma, remains a global burden with limited advancements. Therefore, we study the preclinical and clinical advancements of statins and statins-loaded nanocarriers in head and neck cancer. Data were extracted from various sources, including PubMed, Scopus, and Web of Science. Publications reporting in vitro, in vivo, and clinical data were evaluated. Data will be extracted and assessed following PRISMA guidelines. Various statistical parameters, such as Risk Ratio and Odds Ratio, were computed to analyze the reported clinical trials. This systematic review provides evidence-based proof of the anticancer potential of statins. Research gaps and future perspectives have also been discussed.
Primary Source
Medical oncology (Northwood, London, England)
Ask Prognia AI
Have questions about this review article?
Prognia AI can search this source alongside 35M+ PubMed papers and current ESC, AHA, NICE, and ADA guidelines to give you a fully cited clinical answer.